KRAS and rectal cancer: Dewdney [40] analyzed 165 patients with locally advanced rectal cancer and concluded that the addition of cetuximab did not improve CR or PFS rates; however, RR and OS rates (both secondary endpoints) were significantly improved in patients with wild-type KRAS/BRAF.